Relugolix
Orgovyx, Ryeqo (relugolix) is a small molecule pharmaceutical. Relugolix was first approved as Orgovyx on 2020-12-18. It has been approved in Europe to treat leiomyoma. It is known to target gonadotropin-releasing hormone receptor. Orgovyx's patents are valid until 2037-09-29 (FDA).
| Trade Name | Ryeqo |
|---|---|
| Common Name | Relugolix |
| Indication | leiomyoma |
| Drug Class | Gnrh receptor antagonists (nonpeptide) |
